Novel antibodies as anticancer agents.
In recent years antibodies, whether generated by traditional hybridoma technology or by recombinant DNA strategies, have evolved from Paul Ehrlich's 'magic bullets' to a modern age 'guided missile'. In the recent years of immunologic research, we are witnessing development in the fields of antigen screening and protein engineering in order to create specific anticancer remedies. The developments in the field of recombinant DNA, protein engineering and cancer biology have let us gain insight into many cancer-related mechanisms. Moreover, novel techniques have facilitated tools allowing unique distinction between malignantly transformed cells, and regular ones. This understanding has paved the way for the rational design of a new age of pharmaceuticals: monoclonal antibodies and their fragments. Antibodies can select antigens on both a specific and a high-affinity account, and further implementation of these qualities is used to target cancer cells by specifically identifying exogenous antigens of cancer cell populations. The structure of the antibody provides plasticity resonating from its functional sites. This review will screen some of the many novel antibodies and antibody-based approaches that are being currently developed for clinical applications as the new generation of anticancer agents.
Zafir-Lavie
I
I
Faculty of Biology, Technion-Israel Institute of Technology, Haifa, Israel.
Michaeli
Y
Y
Reiter
Y
Y
D000818:Animals; D000912:Antibodies, Neoplasm / Q000276:immunology* / Q000627:therapeutic use*; D000951:Antigens, Neoplasm / Q000276:immunology; D016207:Cytokines / Q000276:immunology; D006801:Humans; D007167:Immunotherapy; D009369:Neoplasms / Q000098:blood supply / Q000188:drug therapy* / Q000276:immunology* / Q000473:pathology; D011948:Receptors, Antigen, T-Cell / Q000276:immunology
D000912:Antibodies, Neoplasm; D000951:Antigens, Neoplasm; D016207:Cytokines; D011948:Receptors, Antigen, T-Cell